Spravato Uses: What It’s Approved to Treat and What’s Still Being Studied

Written by
Angela Myers
·
Nov 20, 2026
Reviewed by
Ava Meyer, PMHNP-BC, MSN, APRN & MaryEllen Eller, MD

Key takeaways:

  • The FDA has approved two Spravato uses: for treatment-resistant depression and for major depressive disorder with suicidal ideation.
  • For insurance to cover Spravato, it usually must be prescribed for an FDA-approved use. Insurance companies have varying definitions of what counts as treatment-resistant depression, so it’s worth checking your policy if considering this treatment. 
  • Sometimes, Spravato is prescribed for off-label uses. While there is some promising research on Spravato for OCD, anxiety, chronic pain, and other conditions, these are not FDA-approved uses.

There’s nothing more discouraging than taking depression medication consistently without seeing improvement. If you’re experiencing treatment-resistant depression, frustration and hopelessness aren’t the end of the road. “The main thing I want people to know is that there are some really good treatment options. You don’t have to just stay depressed,” says Steve Harvey, MD, regional medical director at Radial and a board-certified psychiatrist. “There's a new generation of treatments out there, including Spravato.”

Spravato is an FDA-approved medication that provides hope for many patients who otherwise haven't had success treating depression. Continue reading to learn more about the two conditions for which Spravato is FDA-approved and what emerging research says about other Spravato uses.

Connect with our Clinicians

Tara Wood
Therapist
Gabriella Farkas
Psychiatrist
Dr. Troy Curry
Staff Psychiatrist
Get in touch

What is Spravato used for?

Spravato is used to treat major depressive disorder (MDD) with suicidal ideation and treatment-resistant depression. But before we get into specifics about Spravato treatment for those conditions, let's review what Spravato is.

Spravato is the brand name for esketamine nasal spray that is FDA-approved and administered in a REMS-certified clinic. Spravato targets glutamate — a brain chemical that plays a role in mood regulation —  instead of serotonin, norepinephrine, or dopamine, which are targeted by most traditional antidepressants. 

Approved use Who it’s for Who it isn’t for Used alone or with an oral antidepressant
Treatment-resistant depression Adults who have tried at least two other antidepressants and haven't experienced relief Adolescents and children; people who have yet to try oral antidepressants; pregnant patients On its own or with an oral antidepressant
MDD with suicidal thoughts or behavior Adults with suicidal ideation Adolescents and children In tandem with an oral antidepressant

Treatment-resistant depression

The first FDA-approved use is for treatment-resistant depression (TRD), which is admittedly a bit misleading. On the surface, the condition seems to be describing  depression that won't respond to any treatments, but this isn’t exactly the case. Instead, Dr. Harvey says that TRD refers to instances where the depression has not responded to two or more oral antidepressants such as SSRIs and SNRIs.

Where it gets complicated is what counts as “trying a medication." Insurance companies often have different policies on who is eligible for Spravato treatment, so it’s worth reading your policy and discussing with a qualified prescriber who understands how the definition of treatment-resistant depression can vary. 

When used for TRD, Spravato can be a monotherapy — or the only antidepressant treatment someone receives. Alternatively, someone can take it in tandem with an oral antidepressant. 

Depression with acute suicidal thoughts or behavior

MDD with suicidal ideation is the second FDA-approved use of Spravato. This is when someone experiences symptoms of MDD along with thoughts about ending one’s life and/or suicidal actions. 

However, there’s an important nuance with this indication. The FDA label states Spravato on its own hasn’t been shown to prevent suicide. To reduce suicidal thoughts, the FDA recommends using it with an oral antidepressant and hospitalization may be necessary if someone cannot remain safe.

You also don’t have to wait until an appointment with a psychiatrist to get help. Immediate crisis support is available for free via the 988 Lifeline.

What is Spravato not approved for?

Spravato is not FDA-approved for any other uses besides treatment-resistant depression and MDD with acute suicidal ideation or behavior. Spravato is not FDA-approved for the following uses:

  • Anesthesia: Ketamine, a drug that’s similar but not the same as esketamine (aka Spravato) is FDA-approved as a general anesthetic. Per a 2025 paper in Advanced Science, esketamine can also have an anesthetic effect, though it’s not approved for this purpose because of the high dose required for it to function as a general anesthetic. 
  • Pain relief: Ketamine and esketamine both impact pain receptors in the brain and spinal cord, according to a 2026 review in the Journal of International Medical Research. Despite this potential use, the FDA has not approved Spravato for chronic pain.
  • Children and teens: The FDA label clearly states that Spravato is not an approved depression treatment for teens and children, because it may increase the risk of suicidal behaviors and thoughts in individuals younger than 18.
  • First-line depression treatment: It’s also not a first-line depression treatment for MDD, unless there is acute suicidal ideation and behavior.
  • Other conditions: While there is some research into Spravato for anxiety, OCD, PTSD, and other mental health conditions, the FDA has not approved this medication for those uses.

Spravato is also not an at-home option. A patient self-administers Spravato in a certified clinic under the supervision of a medical professional. Afterwards, they must remain at the clinic for a 2-hour monitoring period and then arrange a ride home. If someone doesn’t have a way to get to and from the clinic without driving themselves, Dr. Harvey often explores other treatment options, like transcranial magnetic stimulation (TMS).

Can Spravato be prescribed off-label?

Sometimes Spravato is prescribed off-label, which is when a medication is prescribed for a different purpose than the ones on the FDA label. Off-label uses are permitted under US healthcare regulations, per the FDA, though a medical professional must assess if the off-label use is medically necessary. 

Additionally, many insurance plans won’t cover off-label uses, meaning patients might have to pay the entire cost out of pocket. Without insurance coverage, the Spravato cost can be quite high, so off-label use might not work for everyone’s budget.

When prescribed off-label, Spravato is still administered the same way: in a certified clinic with on-site monitoring. The patient must remain at the clinic under medical supervision for no less than two hours. They also need to  arrange for transportation after treatment, since you cannot drive after receiving Spravato until you've had a full night of sleep.

A clinician might consider off-label use of Spravato for bipolar depression, anxious depression, and other conditions that have some clinical evidence to support Spravato’s effectiveness. Sometimes, it may also be prescribed for people who have MDD but have not yet “failed” two or three antidepressants. If, for example, someone had a bad adverse reaction to their first antidepressant, a psychiatrist may recommend Spravato off-label as opposed to another traditional antidepressant. 

What does research say about Spravato for other conditions?

There’s growing  research to support Spravato for PTSD, OCD, and other conditions. However, this research is in its early stages, and none of these emerging uses of  Spravato  are FDA-approved at this time. 

Condition Type of evidence so far Current status
Bipolar disorder Limited to small-scale studies Not FDA-approved
PTSD Promising findings in preliminary clinical trials Not FDA-approved
OCD Limited to small-scale studies Not FDA-approved
Anxiety disorders Limited to small-scale studies Not FDA-approved
Chronic pain Promising findings in preliminary clinical trials Not FDA-approved
  • Bipolar disorder: Case reports and small-scale studies suggest Spravato may be a bipolar disorder treatment for depressive symptoms specifically. For example, in a small-scale study with 25 participants who had treatment-resistant bipolar depression, Spravato led to a reduction in depressive symptoms, per results reported in Bipolar Disorders. 
  • PTSD: According to a narrative review in Behavioral Sciences, multiple studies suggest esketamine may be an effective PTSD treatment for people who also have treatment-resistant depression. However, it comes with the risk of people re-experiencing trauma. In a small-scale study reported in the European Journal of Psychotraumatology, 72.7% of the study’s 16 patients reported trauma re-experiences during Spravato sessions. Not all patients who experienced these symptoms stopped taking Spravato, though six patients did discontinue Spravato treatment.
  • OCD: Spravato might be a possible OCD treatment, per a meta-analysis in Clinical Pharmacology and Therapeutics. However, other treatments such as TMS have significantly more evidence for their effectiveness in treating OCD.
  • Anxiety disorders: While Spravato is not typically used for anxiety without depression, it may help reduce anxiety in people who have both conditions. In a study with 20 patients who had treatment-resistant depression and anxiety, 65% experienced a reduction in anxiety severity, per a 2026 article in BMJPsych.
  • Chronic pain: In a randomized controlled trial with 225 patients, Spravato administration after traumatic lower limb fractures reduced pain and postoperative depression, per a paper in Frontiers in Medicine. Some other studies suggest a similar effect, though research is still emerging.

It’s important to note that the majority of these studies share one thing in common: People had the stated condition and some form of depression. This doesn’t mean Spravato can’t help with these conditions, just that we need to be clear about the full context of the research.

Who should not use Spravato?

While Spravato is a promising treatment for patients with multiple conditions in addition to depression, there are some patients for which Spravato is contraindicated or not recommended. Because Spravato can make psychosis worse and carries the potential for addiction, people who have experienced psychosis or struggled with substance use in the past are not good candidates for Spravato, and active substance use is contraindicated with Spravato.

Other conditions that may indicate you're not a candidate for Spravato include pregnancy, elevated blood pressure, aneurysm, and a history of brain bleeds. What's more, co-prescribing opioids, benzodiazepines, and some sleep medications can increase the risk of adverse events when taking Spravato.

How do you find out whether Spravato is right for you?

The best way to determine if Spravato is right for you is to have a conversation with a qualified prescriber at a certified clinic. Psychiatrists and other mental health providers (like psychiatric-mental health nurse practitioners, or PMHNPs) can prescribe Spravato when they work at a REMS-certified clinic, such as Radial. REMS is a federal program that ensures medications that require specific monitoring are administered in a safe way, including but not limited to Spravato, isotretinoin, and clozapine, to name a few.

During a consultation, a qualified prescriber can determine if you meet standard eligibility requirements, as well as if this medication or another treatment option suits your overall health, lifestyle, and insurance requirements. 

Dr. Harvey reflects that when patients come in with treatment-resistant depression, there are two alternative treatments for depression that he is most likely to explore: transcranial magnetic stimulation (TMS) and Spravato. 

When exploring these options, he considers if the patient has any contraindications (medical reasons they can’t do one or the other) as well as their comfort with each potential treatment.

You can learn more about how the two treatments compare in our TMS vs. Spravato guide.

Relief within reach

Care covered by your insurance

Radial provides advanced mental health treatment, covered by the insurance you already use.

VA
Tricare
Medicare
United Health
Blue Cross Blue Shield
Optum
Cigna
Aetna
Learn more

The bottom line

The main Spravato uses are for treatment-resistant depression and MDD with acute suicidal ideation. For people with these conditions, Spravato may provide rapid, much-needed relief. It may also help with other mental health conditions and chronic pain, though these are off-label uses and are not FDA-approved. To learn more about whether Spravato is right for you, talk to a qualified psychiatric provider, such as the team at Radial. 

Disclaimer: The doctor quoted in this article, Steve Harvey, MD, is a paid speaker for Johnson & Johnson, the manufacturer of Spravato.

Frequently asked questions (FAQs)

Is Spravato a high-risk drug? 

Spravato is a prescription medication that’s classified as a controlled substance. This means that if the drug is misused, there could be adverse effects, including addiction and withdrawal. To combat these risks, Spravato is only administered in certified clinics following FDA-approved treatment protocols once medical necessity is established by a licensed clinician.

Can Spravato be taken at home? 

Spravato cannot be taken at home. While you self-administer this nasal spray, you must do so in a certified clinic and then stay for the mandatory 2-hour minimum medically supervised monitoring period.

Is Spravato the same as ketamine? 

While similar, Spravato and ketamine are not the same thing. Ketamine is a mixture of two mirror-image molecules (R-ketamine and S-ketamine) whereas Spravato contains only S-ketamine. Spravato is FDA-approved for MDD with suicidal ideation and treatment-resistant depression, meaning it’s more likely to be covered by insurance for these uses. Ketamine is FDA-approved only as a general anesthetic.

Editorial Standards

At Radial, we believe better health starts with trusted information. Our mission is to empower readers with accurate, accessible, and compassionate content rooted in evidence-based research and reviewed by qualified medical professionals. We’re committed to ensuring the quality and trustworthiness of our content and editorial process–and providing information that is up-to-date, accurate, and relies on evidence-based research and peer-reviewed journals. Learn more about our editorial process.

Let's connect

Get started with finding the right treatment for you or someone you care about

Get started

Learn more about Radial

Your care starts here

Get started